BHVN - CIK 0001935979
The table below shows Biohaven Ltd.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $103.83M | $141.17M | $184.37M | $187.58M | $157.61M | $314.82M |
| SG&A |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $26.60M |
| $28.21M |
| $27.33M |
| $33.98M |
| $20.56M |
| $18.95M |
| Operating income | -$130.43M | -$169.38M | -$211.70M | -$221.56M | -$178.17M | -$333.77M |
| Income tax | $272.00K | $221.00K | $261.00K | $609.00K | -$59.00K | $177.00K |
| Net income | -$130.53M | -$173.44M | -$198.15M | -$221.68M | -$160.30M | -$319.77M |
| EPS (diluted) | -$0.88 | -$1.64 | -$1.94 | -$2.17 | -$1.70 | -$3.64 |